Literature DB >> 21843059

Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle.

Guido Bocci, Fotios Loupakis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21843059     DOI： 10.2217/pgs.11.75

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  6 in total

1.  Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy.

Authors:  Francesco Pasqualetti; Paola Orlandi; Vittorio Simeon; Martina Cantarella; Daniela Giuliani; Teresa Di Desidero; Alessandra Gonnelli; Durim Delishaj; Giuseppe Lombardi; Andrea Sechi; Marc Sanson; Vittorina Zagonel; Fabiola Paiar; Romano Danesi; Salvatore Guarini; Guido Bocci
Journal:  Mol Neurobiol       Date:  2017-02-01       Impact factor: 5.590

2.  Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.

Authors:  N B Volz; S Stintzing; W Zhang; D Yang; Y Ning; T Wakatsuki; R E El-Khoueiry; J E Li; A Kardosh; F Loupakis; C Cremolini; A Falcone; S J Scherer; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2014-07-29       Impact factor: 3.550

3.  A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients.

Authors:  Luigi Coltelli; Giacomo Allegrini; Paola Orlandi; Chiara Finale; Andrea Fontana; Luna Chiara Masini; Marco Scalese; Giada Arrighi; Maria Teresa Barletta; Ermelinda De Maio; Marta Banchi; Elisabetta Fini; Patrizia Guidi; Giada Frenzilli; Sara Donati; Simona Giovannelli; Lucia Tanganelli; Barbara Salvadori; Lorenzo Livi; Icro Meattini; Ilaria Pazzagli; Marco Di Lieto; Mirco Pistelli; Virginia Casadei; Antonella Ferro; Samanta Cupini; Francesca Orlandi; Damiana Francesca; Giulia Lorenzini; Leonardo Barellini; Alfredo Falcone; Alessandro Cosimi; Guido Bocci
Journal:  NPJ Breast Cancer       Date:  2022-03-21

Review 4.  Pharmacogenetics of anticancer monoclonal antibodies.

Authors:  Dmitrii Shek; Scott A Read; Golo Ahlenstiel; Irina Piatkov
Journal:  Cancer Drug Resist       Date:  2019-03-19

5.  Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.

Authors:  Fotios Loupakis; Chiara Cremolini; Dongyun Yang; Lisa Salvatore; Wu Zhang; Takeru Wakatsuki; Pierre Bohanes; Marta Schirripa; Leonor Benhaim; Sara Lonardi; Carlotta Antoniotti; Giuseppe Aprile; Francesco Graziano; Annamaria Ruzzo; Sara Lucchesi; Monica Ronzoni; Ferdinando De Vita; Giuseppe Tonini; Alfredo Falcone; Heinz-Josef Lenz
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

6.  VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.

Authors:  P Orlandi; A Fontana; A Fioravanti; T Di Desidero; L Galli; L Derosa; B Canu; R Marconcini; E Biasco; A Solini; G Francia; R Danesi; A Falcone; G Bocci
Journal:  Br J Cancer       Date:  2013-07-16       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.